GlassScriptPhysician profile
Swathi Lavudi
NPI 1114367547
$1,441.29
in general payments reported to CMS, 2019-2025
23 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $34.26 · 2021: $170 · 2022: $177 · 2023: $123 · 2024: $362 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $865 · Education: $34.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.51 |
| Education | $34.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $406.84 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $217.16 | 2019-2025 | Krystexxa, Tavneos, Prolia |
| Astrazeneca Pharmaceuticals LP | $122.92 | 2019-2024 | Wainua, Breztri |
| Travere Therapeutics, INC. | $105.82 | 2023-2025 | |
| Vifor Pharma, INC. | $79.17 | 2019-2023 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $77.76 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $65.55 | 2024-2025 | Acthar |
| Exact Sciences Corporation | $52.80 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.78 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $36.67 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $26.04 | 2023 | Tarpeyo |
| Genzyme Corporation | $25.72 | 2024 | |
| Medtronic, INC. | $23.50 | 2025 | Symplicity G3 |
| Scpharmaceuticals INC. | $22.53 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.57 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $16.46 | 2025 | Voquezna |
| Lilly USA, LLC | $16.00 | 2022 | |
| Amicus Therapeutics, INC. | $15.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.29 | 2020 | |
| Sanofi Pasteur INC. | $15.09 | 2019 | |
| Electromed, INC. | $13.91 | 2025 | Smartvest |
| Pfizer INC. | $13.71 | 2025 | |
| Novo Nordisk INC | $13.58 | 2024 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swathi Lavudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.